Rethinking time to diagnosis in cancer survivors: the role of high-flow nasal oxygen
Published
August 7, 2024
Paper ID
PAP-000196
Status
Published
DOI
10.65712/tmj.test000454
Advance Services
Abstract
Background: The cost of time to diagnosis to health systems is substantial. Methods: Eligible participants were cancer survivors. Results: 3072 participants were included (median age 57 years). 3139 participants were included (median age 42 years). Conclusion: Residual confounding cannot be excluded.
Introduction
time to diagnosis remains a leading cause of avoidable harm among cancer survivors.
Practice around high-flow nasal oxygen varies widely between centres. Earlier studies of high-flow nasal oxygen were small or single-centre.
The cost of time to diagnosis to health systems is substantial. time to diagnosis remains a leading cause of avoidable harm among cancer survivors.
Earlier studies of high-flow nasal oxygen were small or single-centre. Practice around high-flow nasal oxygen varies widely between centres. Guidelines make only a weak recommendation on high-flow nasal oxygen.
Discussion
Strengths include the sample size and blinded outcome assessment. These findings suggest that high-flow nasal oxygen is associated with better time to diagnosis in cancer survivors.
Future work should test high-flow nasal oxygen in a pragmatic multicentre trial.
Residual confounding cannot be excluded. These findings suggest that high-flow nasal oxygen is associated with better time to diagnosis in cancer survivors. Future work should test high-flow nasal oxygen in a pragmatic multicentre trial.
Residual confounding cannot be excluded. Strengths include the sample size and blinded outcome assessment.
Conclusions
High-flow nasal oxygen should be considered for cancer survivors to improve time to diagnosis.
References
1. Osei G, Costa E, et al. Home-based cardiac rehabilitation and patient satisfaction. Lancet. 2012;399(5):226-1366.
2. Schmidt N, Rahman J, et al. Delayed cord clamping and time to diagnosis. Lancet. 2021;209(12):390-1312.
3. Tanaka S, Farouk J, et al. Home-based cardiac rehabilitation and 30-day readmission. N Engl J Med. 2018;212(5):306-1400.
4. Farouk S, Larsen R, et al. A sepsis alert system and patient satisfaction. Diabetes Care. 2024;229(2):152-1717.
5. Herrera C, Andersen F, et al. Low-dose aspirin and surgical site infection. BMJ. 2021;243(12):86-1125.
6. Larsen O, Yilmaz U, et al. High-flow nasal oxygen and patient satisfaction. JAMA. 2021;59(11):382-1573.
Appendices
Supplementary tables are available on request.
Materials and Methods
Eligible participants were cancer survivors. Missing data were handled with multiple imputation. We conducted a retrospective cohort study across 5 centres between 2019 and 2025.
Missing data were handled with multiple imputation. Eligible participants were cancer survivors.
The primary outcome was time to diagnosis, assessed blind to allocation. Missing data were handled with multiple imputation. Eligible participants were cancer survivors.
The primary outcome was time to diagnosis, assessed blind to allocation. We conducted a retrospective cohort study across 13 centres between 2018 and 2022. Analyses were adjusted for age, sex and baseline severity.
Results
Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups. time to diagnosis occurred in 8% of the intervention group versus 14% of controls.
4216 participants were included (median age 45 years). time to diagnosis occurred in 13% of the intervention group versus 14% of controls. time to diagnosis occurred in 9% of the intervention group versus 25% of controls. time to diagnosis occurred in 16% of the intervention group versus 22% of controls.
time to diagnosis occurred in 7% of the intervention group versus 21% of controls. time to diagnosis occurred in 12% of the intervention group versus 37% of controls. 4143 participants were included (median age 37 years).
| Group | n | Events | Rate % | OR | 95% CI |
|---|---|---|---|---|---|
| Centre A | 408 | 54 | 39.3 | 0.69 | 0.23–1.4 |
| Age < 65 | 257 | 25 | 26.0 | 0.76 | 0.29–1.16 |
| Age ≥ 65 | 781 | 3 | 39.2 | 0.77 | 0.41–1.35 |
Values are n (%) unless stated otherwise.

Shown for cancer survivors; error bars are 95% confidence intervals.

Shown for cancer survivors; error bars are 95% confidence intervals.
time to diagnosis occurred in 16% of the intervention group versus 13% of controls. The adjusted odds ratio was 0.40 (95% CI 0.23 to 0.62). Effects were consistent across prespecified subgroups.
time to diagnosis occurred in 19% of the intervention group versus 28% of controls. Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.87 (95% CI 0.32 to 0.90). time to diagnosis occurred in 21% of the intervention group versus 21% of controls.